Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lock BsAb
- Development stage
- Preclinical
- Lead developer
- PrecisemAb Biotech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lock BsAb is a multi-specific immune-modulatory antibody candidate developed by PrecisemAb Biotech using its proprietary "Lock" platform. This therapeutic agent is designed to simultaneously engage five distinct pathways to enhance the anti-tumor immune response: it acts as an antagonist to the inhibitory checkpoints PD-1, CTLA-4, and CD47 (the "don't eat me" signal), while simultaneously serving as an agonist for the co-stimulatory receptors 4-1BB (CD137) and CD28. By combining checkpoint blockade with co-stimulatory activation in a single molecule, Lock BsAb aims to overcome the immunosuppressive tumor microenvironment and provide a more potent and targeted activation of both the adaptive and innate immune systems against cancer cells.
- Other names
- PD-1/CTLA-4/4-1BB/CD28/CD47 bispecific antibodyPrecisemAb multi-specific antibody
02
Targets
TNFRSF9 (CD137 extracellular domain)CD28 (Cluster of Differentiation 28)CD47 (Cluster of Differentiation 47)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on Lock BsAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lock BsAb.